Track record · closed signal

Merck & Co., Inc. (MRK) — closed signal from December 5, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on March 5, 2026.

Predicted vs. what happened

MRK price · publication thesis → realized outcomesplit-adjusted
$100.75 Published $114.88 Target $116.07 Window close $125.14 Peak
$94.38 – $99.30Entry zone — fair-value band
$100.75Published — price the day we called it
$114.88Target — the price the thesis aimed for
$125.14Peak — highest point inside the window, not a realized return
$116.07Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 60 days.

Peak price
$125.14
peak on February 25, 2026 — not a realized return
Peak gain
+24.2%
peak, from the publication price
Window close
$116.07
end-of-window price, context only
Days to target
60
Window
December 5, 2025 – March 5, 2026

The thesis — published December 5, 2025

Predicted growth
+15%
over the measurement window
Target price
$114.88
the price the thesis aimed for
Entry zone
$94.38 – $99.30
the fair-value band we waited for
Price at publication
$100.75
published December 5, 2025
Confidence
65%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Merck is a big drug company that has lately seen its stock jump a lot, helped by recent regulatory news for its animal health business. The stock feels popular right now, more than the company's underlying business justifies, so it's safer to wait for a small pullback before buying rather than chasing higher prices.

Primary drivers

  • Strong recent performance among major stocks in the index
  • Recent price momentum after a period of weakness
  • Conditional FDA approval for EXZOLT CATTLE CA1
  • High investor excitement despite modest fundamental scores

How it played out

MRK: target reached in 60 days

Lyra published MRK on 2025-12-05 at $100.75 with 15% expected growth and a $114.88 target. The thesis pointed to strong recent performance among major stocks in the index, price momentum after weakness, conditional FDA approval for EXZOLT CATTLE CA1, and high investor excitement despite modest fundamental scores.

Inside the window, MRK reached the target in 60 days. It peaked at $125.14 on 2026-02-25, with a 24.2% peak gain, so the move went beyond the published target. It ended the window at $116.07, still above the target. The thesis played out.

What happened during the window

On 2026-02-03, Merck reported fourth-quarter 2025 revenue of $16.4 billion, up 5%, and adjusted earnings of $2.04 per share. The same day, Merck gave 2026 revenue guidance of $65.5 billion to $67.0 billion and adjusted earnings guidance of $5.00 to $5.15 per share.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All MRK signals